BioCentury | Dec 16, 2020
Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

...Nancy Stagliano, a biotech veteran who led True North...
...and Origenis. He is Neuron23’s CBO.Prior to True North...
BioCentury | Oct 13, 2020
Product Development

Gilead’s Jyseleca has a leg up over BMS’s Zeposia in biologic-experienced UC patients

...placebo (11.5% vs. 4.2%, p=0.0103). In the True North...
BioCentury | Jun 3, 2020
Finance

June 2 Financial Quick Takes: follow-ons for Allogene, Adaptimmune, plus DCVC Bio, Windtree and BMS

...in the same class as Arena’s etrasimod, met the primary endpoint in the Phase III True North...
BioCentury | Mar 26, 2020
Regulation

FDA finally approves ozanimod for MS, satisfying first criterion for Bristol-Celgene CVR; launch delayed due to COVID-19

...develop Zeposia to treat ulcerative colitis. Data are due in mid-year from the Phase III TRUE NORTH...
BioCentury | Nov 23, 2019
Clinical News

A first-in-class approval for rare anemia could be next step for Sanofi’s sutimlimab

...Bioverativ Inc. in 2018, which in turn got the product through its own takeout of True North...
...Inc. in 2017 for $400 million up front and up to $425 million in milestones. True North’s...
...the classical pathway whereas C5 lies at the end of all three activation pathways (see “True North...
BioCentury | Jan 26, 2018
Company News

Sanofi acquiring Bioverativ for $11.6B

...candidates to treat rare blood diseases. Bioverativ obtained BIVV009 through its acquisition last year of True North...
...NASDAQ:BIVV), Waltham, Mass. Business: Hematology Jennie Walters ALN-AT3 Alprolix BIVV009 efmoroctocog alfa eftrenonacog alfa Eloctate fitusiran SAR439774 Alnylam Pharmaceuticals Inc. Bicycle Therapeutics Ltd. Bioverativ Inc. Sanofi Swedish Orphan Biovitrum AB True North...
BioCentury | Jan 22, 2018
Company News

Sanofi acquiring Bioverativ for $11.6B

...candidates to treat rare blood diseases. Bioverativ obtained BIVV009 through its acquisition last year of True North...
...Bioverativ expect their deal to close within three months. Jennie Walters ALN-AT3 Alprolix BIVV009 Eloctate fitusiran SAR439774 TNT009 Alnylam Pharmaceuticals Inc. Bicycle Therapeutics Ltd. Biogen Inc. Bioverativ Inc. Sanofi True North...
BioCentury | Nov 3, 2017
Clinical News

Celgene reports detailed Phase III data for MS candidate ozanimod

...ECTRIMS-ACTRIMS meeting in Paris. In 2H18, Celgene plans to complete enrollment of the Phase III TRUE NORTH...
BioCentury | Oct 30, 2017
Clinical News

Celgene reports detailed Phase III data for MS candidate ozanimod

...ECTRIMS-ACTRIMS meeting in Paris. In 2H18, Celgene plans to complete enrollment of the Phase III TRUE NORTH...
BioCentury | Oct 28, 2017
Product Development

Chinks in the armor

...modulator Gilenya fingolimod, without sacrificing efficacy. The compound is also in the ongoing Phase III TRUE NORTH...
Items per page:
1 - 10 of 42
BioCentury | Dec 16, 2020
Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

...Nancy Stagliano, a biotech veteran who led True North...
...and Origenis. He is Neuron23’s CBO.Prior to True North...
BioCentury | Oct 13, 2020
Product Development

Gilead’s Jyseleca has a leg up over BMS’s Zeposia in biologic-experienced UC patients

...placebo (11.5% vs. 4.2%, p=0.0103). In the True North...
BioCentury | Jun 3, 2020
Finance

June 2 Financial Quick Takes: follow-ons for Allogene, Adaptimmune, plus DCVC Bio, Windtree and BMS

...in the same class as Arena’s etrasimod, met the primary endpoint in the Phase III True North...
BioCentury | Mar 26, 2020
Regulation

FDA finally approves ozanimod for MS, satisfying first criterion for Bristol-Celgene CVR; launch delayed due to COVID-19

...develop Zeposia to treat ulcerative colitis. Data are due in mid-year from the Phase III TRUE NORTH...
BioCentury | Nov 23, 2019
Clinical News

A first-in-class approval for rare anemia could be next step for Sanofi’s sutimlimab

...Bioverativ Inc. in 2018, which in turn got the product through its own takeout of True North...
...Inc. in 2017 for $400 million up front and up to $425 million in milestones. True North’s...
...the classical pathway whereas C5 lies at the end of all three activation pathways (see “True North...
BioCentury | Jan 26, 2018
Company News

Sanofi acquiring Bioverativ for $11.6B

...candidates to treat rare blood diseases. Bioverativ obtained BIVV009 through its acquisition last year of True North...
...NASDAQ:BIVV), Waltham, Mass. Business: Hematology Jennie Walters ALN-AT3 Alprolix BIVV009 efmoroctocog alfa eftrenonacog alfa Eloctate fitusiran SAR439774 Alnylam Pharmaceuticals Inc. Bicycle Therapeutics Ltd. Bioverativ Inc. Sanofi Swedish Orphan Biovitrum AB True North...
BioCentury | Jan 22, 2018
Company News

Sanofi acquiring Bioverativ for $11.6B

...candidates to treat rare blood diseases. Bioverativ obtained BIVV009 through its acquisition last year of True North...
...Bioverativ expect their deal to close within three months. Jennie Walters ALN-AT3 Alprolix BIVV009 Eloctate fitusiran SAR439774 TNT009 Alnylam Pharmaceuticals Inc. Bicycle Therapeutics Ltd. Biogen Inc. Bioverativ Inc. Sanofi True North...
BioCentury | Nov 3, 2017
Clinical News

Celgene reports detailed Phase III data for MS candidate ozanimod

...ECTRIMS-ACTRIMS meeting in Paris. In 2H18, Celgene plans to complete enrollment of the Phase III TRUE NORTH...
BioCentury | Oct 30, 2017
Clinical News

Celgene reports detailed Phase III data for MS candidate ozanimod

...ECTRIMS-ACTRIMS meeting in Paris. In 2H18, Celgene plans to complete enrollment of the Phase III TRUE NORTH...
BioCentury | Oct 28, 2017
Product Development

Chinks in the armor

...modulator Gilenya fingolimod, without sacrificing efficacy. The compound is also in the ongoing Phase III TRUE NORTH...
Items per page:
1 - 10 of 42